V118C Safety Study in Healthy Adults
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What safety data exists for V118C in humans?
The safety of V118C in humans has not been specifically addressed in the provided research articles. However, these studies highlight that adverse events in phase I trials are common and often unrelated to the drug being tested, emphasizing the importance of careful monitoring and ethical oversight in such trials.12345
What is the purpose of this trial?
The goal of this study is to learn how safe V118 Formulation C is in Healthy Adults and how well people tolerate it.
Research Team
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Eligibility Criteria
This clinical trial is for healthy adults who are in good health before being randomly assigned to a treatment group. Specific eligibility details aren't provided, but typically participants should not have any significant underlying health conditions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intramuscular injections in a 2-dose regimen on Day 1 and Day 29
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- V118C
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University